ClinicalTrials.gg
CompletedNCT05543187Updated Jan 28, 2026Results posted

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

A Phase 3 interventional study of TAK-625 in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Takeda. Completed at 8 sites in Japan. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
1 Month and older
Sex
All
01

Study summary

The main aim of the study is to check if TAK-625 improves symptoms of Progressive Familial Intrahepatic Cholestasis (PFIC), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.

The participants will be treated with TAK-625 for up to the end of study (about 34 months).

Participants will visit their study clinic 15 times from the start of study. After 15 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

02

Conditions studied

  • Progressive Familial Intrahepatic Cholestasis (PFIC)
03

In context

Cholestasis, progressive familial intrahepatic 1

33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 11 interventional studies indexed under Cholestasis, progressive familial intrahepatic 1.

Browse Cholestasis, progressive familial intrahepatic 1 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is Japanese male or female with a body weight >=3.0 kg and who is >=1 month of age at the time of .
  2. The participant has a cholestasis as manifested by total serum bile acid (sBA) >=3\^ (ULN) (applies to the primary cohort only).
  3. The participant has an average morning ItchRO (Obs) score >=1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2). Since it is difficult to evaluate pruritus in infants, participants \<12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.
  4. The caregiver has completed at least 21 valid* morning ItchRO (Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2) (*valid=completed and not answered as "I don't know"; the maximum allowed invalidreports=7, no more than 2 invalid reports during the last 7 days before the baseline visit [Week 0/Visit 2]).
  5. The participant has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) based on:

    Chronic cholestasis as manifested by persistent (>6 months*) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease. (* =\<6 months is acceptable for participants \<12 months of age).

    AND

    For Primary cohort:

    a) The participant has a genetic testing result consistent with disease-causing variation in ABCB11 (PFIC2), based on a genotyping.

    For Supplemental cohort:

    1. The participant has a genetic testing results consistent with disease causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or tight junction protein 2 gene (TJP2) (PFIC4), based on a genotyping.
    2. The participant has a PFIC phenotype without a known mutation or with another known mutation not described above.
    3. The PFIC participant has internal or external biliary diversion surgery history, and the internal or external biliary diversion surgery was reversed.
  6. The participant (whenever possible) and caregiver are able to be contacted by phone for scheduled remote visits (participant contacts [phone calls]).
  7. Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
  8. The same caregiver should be contacted during this study. The ItchRO (Obs) should be completed by the same caregiver for consistency during this study, even if the participant is an adult (over 18 years old).

Exclusion criteria

Exclusion Criteria:

  1. The diagnosed with PFIC2 due to ABCB11 mutation that predicts complete absence of BSEP function due to the type of ABCB11 mutation (t-PFIC2), based on a genotyping (applies to the primary cohort only).
  2. The participant has a diagnosis of benign recurrent intrahepatic cholestasis indicated by a history of intermittent cholestasis with no disease progression.
  3. The participant has a current or recent history (\<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.
  4. The participant has a previous history of surgical interruption of the enterohepatic circulation (applies to the primary cohort only).
  5. The participant with chronic diarrhea requiring intravenous (IV) fluid or nutritional intervention and/or its sequelae at screening or during the 6 months prior to screening.
  6. The participant has a history of liver transplant or currently requires imminent liver transplant.
  7. The participant with decompensated cirrhosis ( [INR] >1.5, and/or albumin \<30 g/L, history, or presence of ascites, and/or variceal hemorrhage, and/or encephalopathy).
  8. The participant has an (ALT) or total serum (TSB) level >15\^ at screening.
  9. The participant has other liver disease.
  10. The participant has any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease), per investigator discretion.
  11. The participant has a possible malignant liver mass in imaging, including screening ultrasound.
  12. The participant has received bile acid, lipid binding resins or ileal bile acid transporter (IBAT) inhibitors within 28 days prior to screening and throughout the trial.
  13. The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    TAK-625, Primary cohort

    TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.

    Drug: TAK-625

  • Experimental
    TAK-625, Supplemental cohort

    TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.

    Drug: TAK-625

Interventions

  • TAK-625 orally, twice daily (BID)

    Also known as: Maralixibat chloride

06

What researchers measure

Primary outcomes

  1. Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26

    The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Average baseline morning ItchRO (Obs) scores were calculated as sum of the morning scores divided by number of morning scores for the 4-week (28 days) time periods (that is \[i.e.\], Day -28 to Day -1). Average morning ItchRO (Obs) scores Week 15 through Week 26 were calculated as the sum of the morning scores divided by the number of morning scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

    Time frame: Baseline to Week 15 through Week 26

Secondary outcomes

  1. Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26

    The ItchRO (Obs) scale measures frequency of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1= A little bit of the time, 2= Some of the time, 3= Most of the time, 4= Almost all of the time/constantly, I don't know) to describe their pruritus condition. 'I don't know' was categorized as missing data. A higher score indicated more severe pruritus. Baseline average morning ItchRO (Obs) frequency scores were calculated as the sum of the morning frequency scores divided by the number of morning severity scores for the 4-week (28 days) time periods. (i.e., Day -28 to Day -1). Average morning ItchRO (Obs) frequency scores of Week 15 through Week 26 were calculated as the sum of the morning frequency scores divided by the number of mornings frequency scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

    Time frame: Baseline to Week 15 through Week 26

  2. Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26

    Change from baseline was calculated as: Post-baseline observed value - Baseline (before first dosing) observed value. Change from baseline in total sBA levels to Week 26 was reported.

    Time frame: Baseline to Week 26

  3. Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 26

    Responders to sBA control were defined as participants who achieved a decrease to less than (\<) 102 mcmol/L, a decrease of greater than (\>) 75 percentage (%), or normalization at any timepoint from baseline through Week 26.

    Time frame: Baseline through Week 26

  4. Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26

    ItchRO (Obs) scale measures severity of pruritus, score ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity was calculated based on daily maximum severity scores from both morning and evening. Average baseline morning and evening ItchRO (Obs) scores were calculated as sum of morning or evening scores divided by number of morning or evening scores for 4-week (28 days) time periods (i.e., Day -28 to Day -1). Average morning and evening ItchRO (Obs) scores Week 15 to Week 26 were calculated as sum of morning or evening scores divided by number of morning or evening scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

    Time frame: Baseline to Week 15 through Week 26

07

Results

Posted Sep 24, 2024

Participant flow

Participants took part in the study at 8 sites in Japan from 10 January 2023 to 22 July 2025.

Participant flow — Overall Study
MilestonePrimary Cohort: TAK-625Supplemental Cohort: TAK-625
Started32
Dosed tak-625 150 mcg/kg32
Dosed tak-625 300 mcg/kg32
Dosed tak-625 450 mcg/kg32
Dosed tak-625 600 mcg/kg32
Completed32
Not completed00

Outcome measures

PrimaryChange in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26

The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Average baseline morning ItchRO (Obs) scores were calculated as sum of the morning scores divided by number of morning scores for the 4-week (28 days) time periods (that is \[i.e.\], Day -28 to Day -1). Average morning ItchRO (Obs) scores Week 15 through Week 26 were calculated as the sum of the morning scores divided by the number of morning scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

Time frame:
Baseline to Week 15 through Week 26
Reported as:
Mean · score on a scale
Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26
score on a scalePrimary Cohort: TAK-625Supplemental Cohort: TAK-625
Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26-1.514 (-3.6541 to 0.6255)-0.202 (-3.6957 to 3.2911)
SecondaryChange in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26

The ItchRO (Obs) scale measures frequency of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1= A little bit of the time, 2= Some of the time, 3= Most of the time, 4= Almost all of the time/constantly, I don't know) to describe their pruritus condition. 'I don't know' was categorized as missing data. A higher score indicated more severe pruritus. Baseline average morning ItchRO (Obs) frequency scores were calculated as the sum of the morning frequency scores divided by the number of morning severity scores for the 4-week (28 days) time periods. (i.e., Day -28 to Day -1). Average morning ItchRO (Obs) frequency scores of Week 15 through Week 26 were calculated as the sum of the morning frequency scores divided by the number of mornings frequency scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

Time frame:
Baseline to Week 15 through Week 26
Reported as:
Mean · score on a scale
Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26
score on a scalePrimary Cohort: TAK-625Supplemental Cohort: TAK-625
Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26-0.740 (-4.8063 to 3.3254)-0.735 (-6.0922 to 4.6213)
SecondaryChange From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26

Change from baseline was calculated as: Post-baseline observed value - Baseline (before first dosing) observed value. Change from baseline in total sBA levels to Week 26 was reported.

Time frame:
Baseline to Week 26
Reported as:
Mean · micromoles per liter (mcmol/L)
Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26
micromoles per liter (mcmol/L)Primary Cohort: TAK-625Supplemental Cohort: TAK-625
Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26-149.900 (-561.4008 to 261.6008)-18.250 (-173.9010 to 137.4010)
SecondaryPercentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 26

Responders to sBA control were defined as participants who achieved a decrease to less than (\<) 102 mcmol/L, a decrease of greater than (\>) 75 percentage (%), or normalization at any timepoint from baseline through Week 26.

Time frame:
Baseline through Week 26
Reported as:
Number · percentage of participants
Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 26
percentage of participantsPrimary Cohort: TAK-625Supplemental Cohort: TAK-625
Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 2633.3 (0.84 to 90.57)0.0 (0.00 to 84.19)
SecondaryChange in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26

ItchRO (Obs) scale measures severity of pruritus, score ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity was calculated based on daily maximum severity scores from both morning and evening. Average baseline morning and evening ItchRO (Obs) scores were calculated as sum of morning or evening scores divided by number of morning or evening scores for 4-week (28 days) time periods (i.e., Day -28 to Day -1). Average morning and evening ItchRO (Obs) scores Week 15 to Week 26 were calculated as sum of morning or evening scores divided by number of morning or evening scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).

Time frame:
Baseline to Week 15 through Week 26
Reported as:
Mean · score on a scale
Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26
score on a scalePrimary Cohort: TAK-625Supplemental Cohort: TAK-625
Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26-1.629 (-3.5064 to 0.2481)-0.254 (-4.3906 to 3.8824)

Adverse events

Collected over From start of study drug administration up to follow-up (up to Week 133). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary Cohort: TAK-6250/3 (0%)0/3 (0%)3/3 (100%)
Supplemental Cohort: TAK-6250/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPrimary Cohort: TAK-625Supplemental Cohort: TAK-625
COVID-19Infections and infestations1/32/2
Upper respiratory tract infectionInfections and infestations3/32/2
DermatitisSkin and subcutaneous tissue disorders2/30/2
NasopharyngitisInfections and infestations2/31/2
Abdominal pain upperGastrointestinal disorders0/31/2
Auricular haematomaInjury, poisoning and procedural complications0/31/2
Blood bilirubin increasedInvestigations0/31/2
ConstipationGastrointestinal disorders0/31/2
GastroenteritisInfections and infestations0/31/2
GingivitisInfections and infestations0/31/2

Baseline characteristics

Intention-to-treat (ITT) included all participants who received at least one dose of study drug. As per-planned analysis, the cohort-wise (primary and supplemental) data were analyzed, collected, and reported in this study.

Age, Continuous
Age, Continuous(years)Primary Cohort: TAK-625Supplemental Cohort: TAK-625Total
Mean7.7 ± 3.218.0 ± 4.247.8 ± 3.11
Sex: Female, Male
Sex: Female, Male(Participants)Primary Cohort: TAK-625Supplemental Cohort: TAK-625Total
Female213
Male112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Primary Cohort: TAK-625Supplemental Cohort: TAK-625Total
Asian325
08

Study locations

8 sites
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki, Japan
  • Yokohamashi Tobu Hospital
    Yokohama, Kanagawa, Japan
  • Tsuyama Chuo Hospital
    Tsuyama, Okayama-ken, Japan
  • Osaka University Hospital
    Suita, Osaka, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Kyoto University Hospital
    Kyoto, Japan
  • Saitama Prefectural Children's Medical Center
    Saitama, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Sep 2023, 7 months.

Results were first posted in Sep 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Jan 10, 2023
Primary completionActual
Sep 4, 2023
CompletionActual
Jul 22, 2025
Results first posted
Sep 24, 2024
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05543187
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Jan 10, 2023
Primary completion
Sep 4, 2023
Completion
Jul 22, 2025
Results posted
Sep 24, 2024
Last update
Jan 28, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion